AWE
SRNE

Avidian Wealth Enterprises’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Avidian Wealth Enterprises’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-92,000
Closed -$106K – 571
2021
Q3 		$106K Buy
92,000
+45,000
+96% +$382K 0.01% 370
2021
Q2 		$153K Buy
+47,000
New +$374K 0.01% 378

Other funds holding SRNE

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Avidian Wealth Enterprises's SRNE Position: Q1 2022 in Review

Avidian Wealth Enterprises sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2022, closing a stake of 106,000 shares — an estimated $493K sold.

Avidian Wealth Enterprises first reported a position in SRNE in Q3 2020 and held it in 6 quarters. The position peaked at $3.94M in Q4 2020. 235 funds tracked by Wall St. Rank hold SRNE as of Q1 2022.

  • Avidian Wealth Enterprises reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
  • Avidian Wealth Enterprises sold 106,000 Sorrento Therapeutics, Inc. shares in Q1 2022, an estimated $493K.
  • Avidian Wealth Enterprises first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and held it in 6 quarters.
  • Avidian Wealth Enterprises's Sorrento Therapeutics, Inc. position peaked at $3.94M in Q4 2020.
  • 235 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2022.

Based on Avidian Wealth Enterprises's 13F filing for Q1 2022, filed 10 May 2022.